eligibility_summary
Inclusion: HER2+ advanced gastric cancer (IHC3+, IHC2+ with SISH/FISH ≥2.0, or proteomic overexpression), progressed after 1 prior systemic therapy, age ≥19, measurable/evaluable per RECIST 1.1, ECOG 0–2, adequate organ function, EF ≥55% or MUGA ≥50%. Exclusion: therapy within 2 wks, grade 3–4 GI bleed <3 mo, arterial thromboembolism <6 mo, uncontrolled infection/cardiac/bleeding disorders, GI perforation/fistula <6 mo, other active cancer <3 yrs (except cured basal cell/thyroid, in situ cervix).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Phase 1b/2, single‑arm, second‑line therapy for HER2‑positive advanced gastric cancer testing trastuzumab + bevacizumab + paclitaxel. Drugs/mechanisms: Trastuzumab (humanized IgG1 monoclonal antibody) binds HER2/ERBB2, blocks receptor signaling and mediates antibody‑dependent cellular cytotoxicity (ADCC), Bevacizumab (humanized IgG1 monoclonal antibody) binds VEGF‑A, inhibiting VEGF‑A/VEGFR1/2 signaling and tumor angiogenesis, Paclitaxel (taxane cytotoxic chemotherapy) stabilizes microtubules, causing mitotic arrest and apoptosis. Targets/pathways: HER2‑overexpressing tumor cells and downstream PI3K/AKT/MAPK signaling, tumor endothelial cells via VEGF‑driven angiogenesis, microtubule dynamics in proliferating cancer cells, immune effector engagement via ADCC.